Tumour hepcidin levels as a biomarker for predicting response to immune checkpoint inhibition in advanced non‐small cell lung cancer

Documents similaires

• Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours
  par: Meghali Goswami, et autres
  Publié: (2024)
• A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non‐small‐cell lung cancer
  par: Van Hieu Mai, et autres
  Publié: (2026)
• Challenges and advances of immune checkpoint therapy
  par: Lingyu Li, et autres
  Publié: (2024)
• Multi‐omics predictive model based on clinical, radiomic and genomic features for predicting the response of limited‐stage small cell lung cancer to definitive chemoradiotherapy
  par: Li Li, et autres
  Publié: (2024)
• A subtype of cancer‐associated fibroblast expressing syndecan‐2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer
  par: Ji‐Yong Sung, et autres
  Publié: (2024)